fluoxetine has been researched along with Anxiety Neuroses in 167 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders." | 9.17 | Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. ( Asbahr, FR; da Costa, CZ; de Morais, RM; Labbadia, EM; Lotufo Neto, F; Morikawa, M; Rodrigues, CL; Turkiewicz, G; Zanetta, DM, 2013) |
| "To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia." | 9.11 | Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005) |
| "An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 9.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
| "In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each." | 9.07 | Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. ( Bernstein, SE; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1993) |
| "These results suggest that fluoxetine may be an effective and safe treatment for nondepressed children and adolescents with anxiety disorders other than OCD and panic disorder." | 7.69 | Fluoxetine for childhood anxiety disorders. ( Balach, L; Birmaher, B; Brodsky, M; Cully, M; Ingram, J; Ryan, N; Waterman, GS, 1994) |
| "Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents." | 6.79 | Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014) |
| "Fluoxetine was effective in reducing the anxiety symptoms and improving functioning in all measures." | 6.71 | Fluoxetine for the treatment of childhood anxiety disorders. ( Axelson, DA; Birmaher, B; Brent, DA; Bridge, J; Clark, DB; Ehmann, M; Heo, J; Kalas, C; Monk, K, 2003) |
| "A new formulation of fluoxetine has been developed that is intended to allow for weekly dosing during the long-term treatment of depression." | 6.70 | Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. ( Dinan, TG, 2001) |
| "A total of sixty male adult Wistar rats with similar body weight and age were randomly divided into 3 groups the blank control group (CON, n=20), the saline control group (SAL, n=20), and the combined medication group (Deanxit +fluoxetine, DF, n=20), then rats in group SAL and group DF were prepared for model of anxiety disorder for 14 days." | 5.51 | Changes of brain-derived neurotrophic factors in rats with generalized anxiety disorder before and after treatment. ( Du, N; Liu, YL; Ma, YY; Wang, LX; Yang, L; Yin, XL, 2022) |
| "The purpose of this study was to test the efficacy of clomipramine and fluoxetine, controlled by placebo, and compare their action in children and adolescents with anxiety disorders." | 5.17 | Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. ( Asbahr, FR; da Costa, CZ; de Morais, RM; Labbadia, EM; Lotufo Neto, F; Morikawa, M; Rodrigues, CL; Turkiewicz, G; Zanetta, DM, 2013) |
| " We compare the effects of 2 combined therapies, fluoxetine and interpersonal therapy (IPT) or fluoxetine and cognitive therapy (CT), on major depression in patients with borderline personality disorder (BPD)." | 5.12 | Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. ( Bellino, S; Bogetto, F; Rinaldi, C; Zizza, M, 2007) |
| "To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia." | 5.11 | Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005) |
| "An 8-week placebo-controlled study, the Research Units on Pediatric Psychopharmacology Anxiety Study, documented beneficial effects of fluvoxamine in the treatment of pediatric social anxiety, separation anxiety, or generalized anxiety disorders." | 5.10 | Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. ( Abikoff, H; Bergman, RL; Davies, M; Fairbanks, J; Gammon, P; Greenhill, L; Hack, S; Klee, B; Klein, R; Labellarte, M; Lynn, D; March, J; McCracken, J; Pine, DS; Riddle, MA; Ritz, L; Roper, M; Sweeney, M; Vitiello, B; Walkup, J, 2002) |
| "Patients who met DSM-IV criteria for major depressive disorder and satisfied eligibility criteria were randomly assigned to once-daily venlafaxine XR, fluoxetine, or placebo for 12 weeks." | 5.09 | Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. ( Ravindran, A; Silverstone, PH, 1999) |
| "Of 67 subjects with depression and/or phobic anxiety, 55 (81%) were eligible to take fluoxetine." | 5.09 | Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial. ( Katona, C; Livingston, G; Manela, M; Stevens, T; Watkin, V, 1999) |
| "An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 5.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
| "In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each." | 5.07 | Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. ( Bernstein, SE; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1993) |
| "Selective serotonin reuptake inhibitors such as fluoxetine that are widely used for the treatment of depression and anxiety disorders produce neuroadaptive change not only in the serotoninergic system but also in other neuromediator systems." | 4.84 | [Neuroadaptive changes in brain during selective serotonin reuptake inhibitors action]. ( Shishkina, GT, 2007) |
| "The demonstrated efficacy in anxiety disorders of drugs such as buspirone or fluoxetine has emphasized the importance of 5-hydroxytryptamine (5-HT or serotonin)." | 4.79 | Serotonin receptor specificity in anxiety disorders. ( Lucki, I, 1996) |
| "The largest body of work supporting the use of medications for childhood anxiety came from studies of obsessive-compulsive disorder, where clomipramine and fluoxetine have been found effective in systematic studies." | 4.79 | Current knowledge of medications for the treatment of childhood anxiety disorders. ( Allen, AJ; Leonard, H; Swedo, SE, 1995) |
| " This study investigated antidepressant-like effects and possible underlying mechanisms of Lactobacillus paracasei PS23 (PS23), live or heat-killed, in a mouse model of corticosterone-induced depression using fluoxetine as standard drug." | 3.91 | Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms. ( Cheng, YF; Hsu, CC; Liao, CL; Tsai, YC; Wang, S; Wei, CL; Wu, CC; Yen, JT, 2019) |
| "The effectiveness of clorazepate dipotassium combined with fluoxetine and a behaviour modification programme for the treatment of anxiety disorders in dogs was investigated." | 3.80 | Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs. ( Anzola, B; Ibáñez, M; Olivares, A; Pineda, S, 2014) |
| "Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine." | 3.76 | Anxiety as a predictor of treatment outcome in children and adolescents with depression. ( Cheung, A; Emslie, G; Kiss, A; Levitt, A; Mayes, T; Michalak, E; Schaffer, A, 2010) |
| "Our work suggests that the combination of the number of comorbid anxiety disorders, an attentional variable, and two planning variables makes it possible to correctly classify 82% of the depressed patients who responded to the treatment with fluoxetine, and 74% of the patients who did not respond to that treatment." | 3.76 | The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. ( Avilés Reyes, R; Camarena, B; Carrillo-Guerrero, MY; Cortés-Penagos, C; Cruz, D; Genis, A; Guàrdia-Olmos, J; Gudayol-Ferré, E; Hernández, S; Herrera-Abarca, JE; Herrera-Guzmán, I; Martínez-Medina, P, 2010) |
| "These results suggest that fluoxetine may be an effective and safe treatment for nondepressed children and adolescents with anxiety disorders other than OCD and panic disorder." | 3.69 | Fluoxetine for childhood anxiety disorders. ( Balach, L; Birmaher, B; Brodsky, M; Cully, M; Ingram, J; Ryan, N; Waterman, GS, 1994) |
| "Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months." | 3.68 | Fluoxetine in panic disorder. ( Campeas, R; Davies, SO; Fairbanks, J; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR, 1990) |
| "Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents." | 2.79 | Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014) |
| "Fluoxetine was superior to no therapy in the treatment of depression but not anxiety." | 2.73 | Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine. ( Alipor, A; Esmaelzadeh, S; Faramarzi, M; Kheirkhah, F; Pash, H; Poladi, K, 2008) |
| "Patients with depression are often excluded from studies on the treatment of social anxiety disorder (SAD), leaving gaps in our knowledge about the impact of depressive affect on treatment for SAD." | 2.71 | Impact of depressive symptoms on the treatment of generalized social anxiety disorder. ( Davidson, JR; Foa, EB; Huppert, JD; Keefe, FJ; Ledley, DR; Potts, NL, 2005) |
| "Pemoline was associated with a significant decrease in the high frequency (HF) power (0." | 2.71 | Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans. ( Balon, R; Doll, RG; Jayaraman, A; Pohl, R; Yeragani, V, 2003) |
| "Fluoxetine was effective in reducing the anxiety symptoms and improving functioning in all measures." | 2.71 | Fluoxetine for the treatment of childhood anxiety disorders. ( Axelson, DA; Birmaher, B; Brent, DA; Bridge, J; Clark, DB; Ehmann, M; Heo, J; Kalas, C; Monk, K, 2003) |
| "Fluoxetine was significantly different from placebo only on the HAD depression subscale score." | 2.70 | Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. ( Salinas, E; Silverstone, PH, 2001) |
| "A new formulation of fluoxetine has been developed that is intended to allow for weekly dosing during the long-term treatment of depression." | 2.70 | Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder. ( Dinan, TG, 2001) |
| "Fluoxetine treatment had a more rapid effect and greater impact upon anxiety symptoms, while CBT was associated with increased use of cognitive and behavioural coping strategies and a shift from a biomedical to a biopsychosocial causal attribution of premenstrual symptoms." | 2.70 | Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. ( Browne, S; Cariss, M; Hunter, MS; Jelley, R; Katz, M; Ussher, JM, 2002) |
| "fluoxetine in the treatment of patients with depression and anxiety." | 2.70 | Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. ( De Bleeker, E; De Nayer, A; Evrard, JL; Fossion, P; Geerts, S; Leyman, S; Linkowski, P; Mignon, A; Ruelens, L; Schittecatte, M; Van Eeckhoutte, I, 2002) |
| "We examine whether baseline anxiety or insomnia symptoms (1) show differential response to fluoxetine or imipramine or (2) predict differences between drugs in overall clinical response or likelihood of medication discontinuation." | 2.69 | Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. ( Grothaus, L; Heiligenstein, JH; Katon, W; Revicki, D; Simon, GE, 1998) |
| "Fluoxetine was given at a fixed dose of 20 mg/day and amitriptyline was given in a range of 50-250 mg/day (mean of 138." | 2.69 | Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison. ( Dávila, J; Mata, S; Mazzotti, G; Ontiveros, A; Ospina, J; Pacheco, A; Palacios, M; Plewes, J; Tamura, R; Versiani, M, 1999) |
| "Of 115 cancer patients who fulfilled entry criteria for levels of distress, 45 patients were randomized to a fluoxetine treatment group (FA) and 46 patients to a placebo group (PA) after a 1-week placebo period designed to exclude placebo responders." | 2.68 | The effect of fluoxetine on anxiety and depression symptoms in cancer patients. ( Allilaire, JF; Blin, P; Bouhassira, M; Cordier, B; Desclaux, B; Fresco, R; Gauvain-Piquard, A; Guillibert, E; Mesters, P; Orth, JP; Piollet, I; Razavi, D; Salimpour, A; Saltel, P; Sechter, D; Smith, M; Trichard, C; Verra, M, 1996) |
| "Fluoxetine was well tolerated and showed rapid onset of action." | 2.68 | Fluoxetine in the treatment of anger: an open clinical trial. ( Emmanuel, N; Johnson, MR; Lydiard, RB; Rubey, RN, 1996) |
| "Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment." | 2.40 | Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999) |
| "Fluoxetine was significantly (p < or = ." | 2.39 | Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. ( Holman, SL; Potvin, JH; Sayler, ME; Tollefson, GD, 1994) |
| "Investigating adverse events associated with antidepressant treatments in adolescents is important given the concerns about increased risk of suicidal ideation and behavior in this age group." | 1.51 | Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine. ( Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019) |
| "Women with major depressive disorder during pregnancy often use selective serotonin reuptake inhibitors (SSRIs) antidepressants." | 1.46 | Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity. ( Avitsur, R, 2017) |
| "(DSM-IV) criteria for major depressive disorder (MDD) or anxiety disorders participated in study." | 1.43 | The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders. ( Amitai, M; Apter, A; Carmel, M; Chen, A; Eilat, T; Fennig, S; Michaelovsky, E; Orpaz, N; Taler, M; Weizman, A; Yablonski, M, 2016) |
| "Sulforaphane (SFN) is a natural compound with antioxidative, anti-inflammatory and neuroprotective activities." | 1.43 | Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice. ( Gao, Q; Gao, Y; Liang, Y; Ma, Y; Shi, H; Wang, X; Wu, S; Xi, Y; Zhao, P, 2016) |
| "Fluoxetine treatment in adulthood evokes antidepressant and anxiolytic responses." | 1.40 | Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. ( Chachra, P; Desouza, LA; Kennedy, P; Nestler, EJ; Pena, CJ; Sarkar, A; Vaidya, VA, 2014) |
| "Fluoxetine treatment increased synaptic plasticity, converted the fear memory circuitry to a more immature state, and acted through local brain-derived neurotrophic factor." | 1.37 | Fear erasure in mice requires synergy between antidepressant drugs and extinction training. ( Agústsdóttir, A; Akamine, Y; Antila, H; Bahi, A; Castrén, E; Drew, LJ; Hen, R; Karpova, NN; Kulesskaya, N; Lindholm, J; Pickenhagen, A; Popova, D; Sullivan, R; Tiraboschi, E, 2011) |
| "Fluoxetine was ineffective in pinealectomized C3H or C57BL6 mice." | 1.32 | The pineal gland and anxiogenic-like action of fluoxetine in mice. ( Akhisaroglu, M; Dimitrijevic, N; Imbesi, M; Kurtuncu, M; Manev, H; Uz, T, 2004) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| "Fluvoxamine was shown to be a safe drug and no unexpected or previously undetected drug-related events were encountered." | 1.29 | Prescription-event monitoring of 10,401 patients treated with fluvoxamine. ( Edwards, JG; Inman, WH; Pearce, GL; Wilton, L, 1994) |
| "Selective mutism is a rare disorder with poor treatment outcome." | 1.29 | Case study: fluoxetine in the multimodal treatment of a preschool child with selective mutism. ( Anderson, JH; Cuccaro, ML; Kendall, DF; Leonhardt, TV; Wright, HH, 1995) |
| "Fluoxetine, which has a long half-life, was more difficult to titrate." | 1.28 | Apathy and indifference in patients on fluvoxamine and fluoxetine. ( Hoehn-Saric, R; Lipsey, JR; McLeod, DR, 1990) |
| "Fluoxetine is a new antidepressant with pharmacologic effects apparently limited to blockade of neuronal serotonin reuptake." | 1.27 | An open trial of fluoxetine in the treatment of panic attacks. ( Campeas, RB; Davies, SO; Fyer, AJ; Fyer, MR; Goetz, D; Gorman, JM; Klein, DF; Liebowitz, MR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.20) | 18.7374 |
| 1990's | 61 (36.53) | 18.2507 |
| 2000's | 48 (28.74) | 29.6817 |
| 2010's | 42 (25.15) | 24.3611 |
| 2020's | 14 (8.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira-Garcia, R | 1 |
| Costa, MA | 1 |
| Gonçalves, FG | 1 |
| de Nonohay, RG | 1 |
| Nardi, AE | 1 |
| Freire, RCDR | 1 |
| Manfro, GG | 1 |
| Legg, LA | 1 |
| Rudberg, AS | 1 |
| Hua, X | 1 |
| Wu, S | 2 |
| Hackett, ML | 1 |
| Tilney, R | 1 |
| Lindgren, L | 1 |
| Kutlubaev, MA | 1 |
| Hsieh, CF | 1 |
| Barugh, AJ | 1 |
| Hankey, GJ | 1 |
| Lundström, E | 1 |
| Dennis, M | 1 |
| Mead, GE | 1 |
| Yin, XL | 1 |
| Ma, YY | 1 |
| Liu, YL | 1 |
| Wang, LX | 1 |
| Du, N | 1 |
| Yang, L | 1 |
| Izquierdo Romero, M | 1 |
| Rodríguez Prida, J | 1 |
| Hermida Pérez, B | 1 |
| Salman Monte, Z | 1 |
| Troy, TF | 1 |
| Poweleit, EA | 1 |
| Strawn, JR | 2 |
| Martin, LJ | 1 |
| Ramsey, LB | 1 |
| Houwing, DJ | 2 |
| Schuttel, K | 1 |
| Struik, EL | 1 |
| Arling, C | 1 |
| Ramsteijn, AS | 1 |
| Heinla, I | 1 |
| Olivier, JDA | 1 |
| Zhou, Y | 1 |
| Arend, J | 1 |
| Mufson, L | 1 |
| Gunlicks-Stoessel, M | 1 |
| Amitai, M | 2 |
| Taler, M | 2 |
| Lebow, M | 1 |
| Ben-Baruch, R | 1 |
| Apter, A | 2 |
| Fennig, S | 2 |
| Weizman, A | 2 |
| Chen, A | 2 |
| Ebberwein, CA | 1 |
| Hopper, MT | 1 |
| Vedala, R | 1 |
| Macaluso, MM | 1 |
| Hamill Skoch, S | 1 |
| Mills, JA | 1 |
| Ramsey, L | 1 |
| Bashiri, H | 1 |
| Homberg, JR | 2 |
| Salari, AA | 2 |
| Panayotis, N | 1 |
| Freund, PA | 1 |
| Marvaldi, L | 1 |
| Shalit, T | 1 |
| Brandis, A | 1 |
| Mehlman, T | 1 |
| Tsoory, MM | 1 |
| Fainzilber, M | 1 |
| Peterson, BS | 1 |
| West, AE | 1 |
| Weisz, JR | 1 |
| Mack, WJ | 1 |
| Kipke, MD | 1 |
| Findling, RL | 1 |
| Mittman, BS | 1 |
| Bansal, R | 1 |
| Piantadosi, S | 1 |
| Takata, G | 1 |
| Koebnick, C | 1 |
| Ashen, C | 1 |
| Snowdy, C | 1 |
| Poulsen, M | 1 |
| Arora, BK | 1 |
| Allem, CM | 1 |
| Perez, M | 1 |
| Marcy, SN | 1 |
| Hudson, BO | 1 |
| Chan, SH | 1 |
| Weersing, R | 1 |
| Avitsur, R | 1 |
| Bogi, E | 1 |
| Belovicová, K | 1 |
| Ujhazy, E | 1 |
| Mach, M | 1 |
| Koprdova, R | 1 |
| Zilava, L | 1 |
| Garafová, A | 1 |
| Jezova, D | 1 |
| Dubovicky, M | 1 |
| Simard, S | 1 |
| Shail, P | 1 |
| MacGregor, J | 1 |
| El Sayed, M | 1 |
| Duman, RS | 1 |
| Vaccarino, FM | 1 |
| Salmaso, N | 1 |
| Yoon, W | 1 |
| Shon, SH | 1 |
| Hong, Y | 1 |
| Joo, YH | 1 |
| Lee, JS | 1 |
| Melvin, GA | 1 |
| Finnin, L | 1 |
| Taffe, J | 1 |
| Dudley, AL | 1 |
| Klimkeit, EI | 1 |
| Gordon, MS | 1 |
| Tonge, B | 1 |
| Wei, CL | 1 |
| Wang, S | 2 |
| Yen, JT | 1 |
| Cheng, YF | 1 |
| Liao, CL | 1 |
| Hsu, CC | 1 |
| Wu, CC | 1 |
| Tsai, YC | 1 |
| Akaltun, İ | 1 |
| Ayaydin, H | 1 |
| Thorkelson, G | 1 |
| Laughlin, SF | 1 |
| Turner, KS | 1 |
| Ober, N | 1 |
| Handen, BL | 1 |
| Schwartz, C | 1 |
| Barican, JL | 1 |
| Yung, D | 1 |
| Zheng, Y | 1 |
| Waddell, C | 1 |
| Day, C | 1 |
| Higginbottom, KB | 1 |
| Aderka, IM | 1 |
| McLean, CP | 1 |
| Huppert, JD | 2 |
| Davidson, JR | 4 |
| Foa, EB | 2 |
| Epelbaum, S | 1 |
| Dubois, B | 1 |
| da Costa, CZ | 1 |
| de Morais, RM | 1 |
| Zanetta, DM | 1 |
| Turkiewicz, G | 1 |
| Lotufo Neto, F | 1 |
| Morikawa, M | 1 |
| Rodrigues, CL | 1 |
| Labbadia, EM | 1 |
| Asbahr, FR | 1 |
| Pineda, S | 1 |
| Anzola, B | 1 |
| Olivares, A | 1 |
| Ibáñez, M | 1 |
| Bottelier, MA | 1 |
| Schouw, ML | 1 |
| Klomp, A | 1 |
| Tamminga, HG | 1 |
| Schrantee, AG | 1 |
| Bouziane, C | 1 |
| de Ruiter, MB | 1 |
| Boer, F | 1 |
| Ruhé, HG | 1 |
| Denys, D | 1 |
| Rijsman, R | 1 |
| Lindauer, RJ | 1 |
| Reitsma, HB | 1 |
| Geurts, HM | 1 |
| Reneman, L | 1 |
| Sarkar, A | 1 |
| Chachra, P | 1 |
| Kennedy, P | 1 |
| Pena, CJ | 1 |
| Desouza, LA | 1 |
| Nestler, EJ | 1 |
| Vaidya, VA | 1 |
| Blázquez, A | 3 |
| Mas, S | 3 |
| Plana, MT | 2 |
| Gassó, P | 3 |
| Méndez, I | 1 |
| Torra, M | 1 |
| Arnaiz, JA | 3 |
| Lafuente, A | 3 |
| Lázaro, L | 3 |
| Kheirbek, MA | 1 |
| Hen, R | 3 |
| McEwen, BS | 1 |
| Simons, A | 1 |
| Steyaert, J | 1 |
| Altieri, SC | 1 |
| Yang, H | 1 |
| O'Brien, HJ | 1 |
| Redwine, HM | 1 |
| Senturk, D | 1 |
| Hensler, JG | 1 |
| Andrews, AM | 1 |
| Gao, Q | 1 |
| Zhao, P | 1 |
| Gao, Y | 1 |
| Xi, Y | 1 |
| Wang, X | 1 |
| Liang, Y | 1 |
| Shi, H | 1 |
| Ma, Y | 1 |
| Carmel, M | 1 |
| Michaelovsky, E | 1 |
| Eilat, T | 1 |
| Yablonski, M | 1 |
| Orpaz, N | 1 |
| Fatehi-Gharehlar, L | 1 |
| Motayagheni, N | 1 |
| Taguchi, R | 1 |
| Shikata, K | 1 |
| Furuya, Y | 1 |
| Ino, M | 1 |
| Shin, K | 1 |
| Shibata, H | 1 |
| Sevi Tok, ES | 1 |
| Arkar, H | 1 |
| Bildik, T | 1 |
| Marcinkiewcz, CA | 1 |
| Mazzone, CM | 1 |
| D'Agostino, G | 1 |
| Halladay, LR | 1 |
| Hardaway, JA | 1 |
| DiBerto, JF | 1 |
| Navarro, M | 1 |
| Burnham, N | 1 |
| Cristiano, C | 1 |
| Dorrier, CE | 1 |
| Tipton, GJ | 1 |
| Ramakrishnan, C | 1 |
| Kozicz, T | 1 |
| Deisseroth, K | 1 |
| Thiele, TE | 1 |
| McElligott, ZA | 1 |
| Holmes, A | 2 |
| Heisler, LK | 1 |
| Kash, TL | 1 |
| Rodríguez, N | 2 |
| Boloc, D | 2 |
| Monteagudo, A | 1 |
| Papakostas, GI | 3 |
| McGrath, P | 1 |
| Stewart, J | 1 |
| Charles, D | 1 |
| Chen, Y | 1 |
| Mischoulon, D | 2 |
| Dording, C | 1 |
| Fava, M | 6 |
| Purper-Ouakil, D | 1 |
| Vidair, HB | 1 |
| Gunlicks-Stoessel, ML | 1 |
| Filho, AS | 1 |
| Carvalho, DL | 1 |
| Tumas, V | 1 |
| Hetem, LA | 1 |
| Ferrari, MC | 1 |
| Crippa, JA | 1 |
| Sussman, N | 1 |
| Zhang, J | 1 |
| Huang, XY | 1 |
| Ye, ML | 1 |
| Luo, CX | 1 |
| Wu, HY | 1 |
| Hu, Y | 1 |
| Zhou, QG | 1 |
| Wu, DL | 1 |
| Zhu, LJ | 1 |
| Zhu, DY | 1 |
| Maslowsky, J | 1 |
| Mogg, K | 1 |
| Bradley, BP | 1 |
| McClure-Tone, E | 1 |
| Ernst, M | 2 |
| Pine, DS | 4 |
| Monk, CS | 2 |
| Cheung, A | 1 |
| Mayes, T | 1 |
| Levitt, A | 1 |
| Schaffer, A | 1 |
| Michalak, E | 1 |
| Kiss, A | 1 |
| Emslie, G | 1 |
| Gudayol-Ferré, E | 1 |
| Herrera-Guzmán, I | 1 |
| Camarena, B | 1 |
| Cortés-Penagos, C | 1 |
| Herrera-Abarca, JE | 1 |
| Martínez-Medina, P | 1 |
| Cruz, D | 1 |
| Hernández, S | 1 |
| Genis, A | 1 |
| Carrillo-Guerrero, MY | 1 |
| Avilés Reyes, R | 1 |
| Guàrdia-Olmos, J | 1 |
| Farabaugh, A | 2 |
| Sonawalla, S | 1 |
| Johnson, DP | 1 |
| Witte, J | 1 |
| Goodness, T | 1 |
| Clain, A | 1 |
| Baer, L | 1 |
| Harley, R | 1 |
| Silk, JS | 1 |
| Forbes, EE | 1 |
| Whalen, DJ | 1 |
| Jakubcak, JL | 1 |
| Thompson, WK | 1 |
| Ryan, ND | 1 |
| Axelson, DA | 2 |
| Birmaher, B | 4 |
| Dahl, RE | 1 |
| Patel, V | 1 |
| Weiss, HA | 1 |
| Chowdhary, N | 1 |
| Naik, S | 1 |
| Pednekar, S | 1 |
| Chatterjee, S | 1 |
| De Silva, MJ | 1 |
| Bhat, B | 1 |
| Araya, R | 1 |
| King, M | 1 |
| Simon, G | 1 |
| Verdeli, H | 1 |
| Kirkwood, BR | 1 |
| Rainer, Q | 1 |
| Xia, L | 1 |
| Guilloux, JP | 1 |
| Gabriel, C | 1 |
| Mocaër, E | 1 |
| Enhamre, E | 1 |
| Gardier, AM | 1 |
| David, DJ | 1 |
| Vicente, MA | 1 |
| Zangrossi, H | 1 |
| Taurines, R | 1 |
| Gerlach, M | 1 |
| Warnke, A | 1 |
| Thome, J | 1 |
| Wewetzer, C | 1 |
| Karpova, NN | 1 |
| Pickenhagen, A | 1 |
| Lindholm, J | 1 |
| Tiraboschi, E | 1 |
| Kulesskaya, N | 1 |
| Agústsdóttir, A | 1 |
| Antila, H | 1 |
| Popova, D | 1 |
| Akamine, Y | 1 |
| Bahi, A | 1 |
| Sullivan, R | 1 |
| Drew, LJ | 1 |
| Castrén, E | 1 |
| Lin, YL | 1 |
| Lin, SY | 1 |
| Camp, MC | 1 |
| Macpherson, KP | 1 |
| Lederle, L | 1 |
| Graybeal, C | 1 |
| Gaburro, S | 1 |
| Debrouse, LM | 1 |
| Ihne, JL | 1 |
| Bravo, JA | 1 |
| O'Connor, RM | 1 |
| Ciocchi, S | 1 |
| Wellman, CL | 1 |
| Lüthi, A | 1 |
| Cryan, JF | 1 |
| Singewald, N | 1 |
| Steinberg, EM | 1 |
| Cardoso, GM | 1 |
| Martinez, PE | 1 |
| Rubinow, DR | 1 |
| Schmidt, PJ | 1 |
| De Nayer, A | 1 |
| Geerts, S | 1 |
| Ruelens, L | 1 |
| Schittecatte, M | 1 |
| De Bleeker, E | 1 |
| Van Eeckhoutte, I | 1 |
| Evrard, JL | 1 |
| Linkowski, P | 1 |
| Fossion, P | 1 |
| Leyman, S | 1 |
| Mignon, A | 1 |
| Meoni, P | 1 |
| Haudiquet, V | 1 |
| Cantillon, M | 1 |
| Hackett, D | 1 |
| Hunter, MS | 1 |
| Ussher, JM | 1 |
| Cariss, M | 1 |
| Browne, S | 1 |
| Jelley, R | 1 |
| Katz, M | 1 |
| Sonawalla, SB | 1 |
| Johnson, MW | 1 |
| Morray, M | 1 |
| Delgado, ML | 1 |
| Pingol, MG | 1 |
| Rosenbaum, JF | 3 |
| Walkup, J | 1 |
| Labellarte, M | 1 |
| Riddle, MA | 1 |
| Greenhill, L | 1 |
| Fairbanks, J | 3 |
| Klein, R | 1 |
| Davies, M | 1 |
| Sweeney, M | 1 |
| Abikoff, H | 1 |
| Hack, S | 2 |
| Klee, B | 1 |
| Bergman, RL | 1 |
| Lynn, D | 1 |
| McCracken, J | 1 |
| March, J | 1 |
| Gammon, P | 1 |
| Vitiello, B | 1 |
| Ritz, L | 1 |
| Roper, M | 1 |
| Monk, K | 2 |
| Kalas, C | 2 |
| Clark, DB | 2 |
| Ehmann, M | 2 |
| Bridge, J | 2 |
| Heo, J | 1 |
| Brent, DA | 1 |
| Harper, A | 1 |
| Hugo, C | 1 |
| Seier, J | 1 |
| Mdhluli, C | 1 |
| Daniels, W | 1 |
| Harvey, BH | 1 |
| Du Toit, D | 1 |
| Wolfe-Coote, S | 1 |
| Nel, D | 1 |
| Stein, DJ | 1 |
| Feiger, AD | 1 |
| Flament, MF | 1 |
| Boyer, P | 1 |
| Gillespie, JA | 1 |
| Pohl, R | 2 |
| Balon, R | 2 |
| Jayaraman, A | 1 |
| Doll, RG | 1 |
| Yeragani, V | 1 |
| Williams, TP | 1 |
| Miller, BD | 1 |
| Boerner, RJ | 1 |
| Uz, T | 1 |
| Dimitrijevic, N | 1 |
| Akhisaroglu, M | 1 |
| Imbesi, M | 1 |
| Kurtuncu, M | 1 |
| Manev, H | 1 |
| Cassano, P | 1 |
| Soares, CN | 1 |
| Cohen, LS | 1 |
| Lyster, AK | 1 |
| Cyranowski, JM | 1 |
| Frank, E | 1 |
| Shear, MK | 1 |
| Swartz, H | 1 |
| Fagiolini, A | 1 |
| Scott, J | 1 |
| Kupfer, DJ | 1 |
| Pollack, MH | 6 |
| Simon, NM | 3 |
| Zalta, AK | 3 |
| Worthington, JJ | 2 |
| Hoge, EA | 2 |
| Mick, E | 1 |
| Kinrys, G | 1 |
| Oppenheimer, J | 1 |
| Ledley, DR | 1 |
| Keefe, FJ | 1 |
| Potts, NL | 1 |
| Axelson, D | 1 |
| Wood, DS | 1 |
| Muthen, B | 1 |
| Brent, D | 1 |
| Nelson, JC | 2 |
| Portera, L | 1 |
| Leon, AC | 1 |
| Leveleki, C | 1 |
| Sziray, N | 1 |
| Levay, G | 1 |
| Barsvári, B | 1 |
| Soproni, K | 1 |
| Mikics, E | 1 |
| Haller, J | 1 |
| Safer, DJ | 1 |
| McClure, EB | 1 |
| Adler, A | 1 |
| Cameron, J | 1 |
| Smith, S | 1 |
| Nelson, EE | 1 |
| Leibenluft, E | 1 |
| Christian, KM | 2 |
| Stevens, JC | 1 |
| Petersen, T | 1 |
| Sklarsky, KG | 1 |
| Nierenberg, AA | 1 |
| Alpert, JE | 2 |
| Greenwood, BN | 1 |
| Strong, PV | 1 |
| Foley, TE | 1 |
| Thompson, RS | 1 |
| Fleshner, M | 1 |
| Olatunji, BO | 1 |
| Feldman, G | 1 |
| Smits, JA | 1 |
| Menza, MA | 1 |
| Dobkin, RD | 1 |
| Marin, H | 1 |
| Vaishnavi, S | 1 |
| Connor, K | 1 |
| Stemmelin, J | 1 |
| Cohen, C | 1 |
| Terranova, JP | 1 |
| Lopez-Grancha, M | 1 |
| Pichat, P | 1 |
| Bergis, O | 1 |
| Decobert, M | 1 |
| Santucci, V | 1 |
| Françon, D | 1 |
| Alonso, R | 1 |
| Stahl, SM | 1 |
| Keane, P | 1 |
| Avenet, P | 1 |
| Scatton, B | 1 |
| le Fur, G | 1 |
| Griebel, G | 1 |
| Faramarzi, M | 1 |
| Alipor, A | 1 |
| Esmaelzadeh, S | 1 |
| Kheirkhah, F | 1 |
| Poladi, K | 1 |
| Pash, H | 1 |
| Shishkina, GT | 1 |
| Leonard, SK | 1 |
| Dwyer, JM | 1 |
| Sukoff Rizzo, SJ | 1 |
| Platt, B | 1 |
| Logue, SF | 1 |
| Neal, SJ | 1 |
| Malberg, JE | 1 |
| Beyer, CE | 1 |
| Schechter, LE | 1 |
| Rosenzweig-Lipson, S | 1 |
| Ring, RH | 1 |
| Katz, LY | 1 |
| Kozyrskyj, AL | 1 |
| Prior, HJ | 1 |
| Enns, MW | 1 |
| Cox, BJ | 1 |
| Sareen, J | 1 |
| Bellino, S | 1 |
| Zizza, M | 1 |
| Rinaldi, C | 1 |
| Bogetto, F | 1 |
| Wright, HH | 1 |
| Cuccaro, ML | 1 |
| Leonhardt, TV | 1 |
| Kendall, DF | 1 |
| Anderson, JH | 1 |
| Allen, AJ | 1 |
| Leonard, H | 1 |
| Swedo, SE | 1 |
| Finley, PR | 1 |
| Lapierre, YD | 1 |
| Waterman, GS | 1 |
| Ryan, N | 1 |
| Cully, M | 1 |
| Balach, L | 1 |
| Ingram, J | 1 |
| Brodsky, M | 1 |
| Maddocks, A | 1 |
| Edwards, JG | 1 |
| Inman, WH | 1 |
| Wilton, L | 1 |
| Pearce, GL | 1 |
| Manassis, K | 1 |
| Bradley, S | 1 |
| Tollefson, GD | 1 |
| Holman, SL | 1 |
| Sayler, ME | 1 |
| Potvin, JH | 1 |
| Jackson, CW | 1 |
| Morton, WA | 1 |
| Lydiard, RB | 2 |
| Yeragani, VK | 1 |
| Ramesh, C | 1 |
| Lebert, F | 1 |
| Pasquier, F | 1 |
| Goudemand, M | 1 |
| Petit, H | 1 |
| Phillips, KA | 1 |
| McElroy, SL | 1 |
| Keck, PE | 1 |
| Pope, HG | 1 |
| Hudson, JI | 1 |
| Grady, TA | 1 |
| Pigott, TA | 1 |
| L'Heureux, F | 1 |
| Hill, JL | 2 |
| Bernstein, SE | 1 |
| Murphy, DL | 2 |
| Berlin, CS | 1 |
| Friedenberg, FK | 1 |
| Rothstein, KD | 1 |
| Serra-Mestres, J | 1 |
| Shapleske, J | 1 |
| Tym, E | 1 |
| Warshaw, MG | 1 |
| Keller, MB | 1 |
| Lucki, I | 1 |
| Hanes, KR | 1 |
| Razavi, D | 1 |
| Allilaire, JF | 1 |
| Smith, M | 1 |
| Salimpour, A | 1 |
| Verra, M | 1 |
| Desclaux, B | 1 |
| Saltel, P | 1 |
| Piollet, I | 1 |
| Gauvain-Piquard, A | 1 |
| Trichard, C | 1 |
| Cordier, B | 1 |
| Fresco, R | 1 |
| Guillibert, E | 1 |
| Sechter, D | 1 |
| Orth, JP | 1 |
| Bouhassira, M | 2 |
| Mesters, P | 1 |
| Blin, P | 1 |
| Flint, AJ | 2 |
| Rifat, SL | 2 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Fairbanks, JM | 1 |
| Tancer, NK | 1 |
| Dummit, ES | 1 |
| Kentgen, LM | 1 |
| Martin, J | 1 |
| Asche, BK | 1 |
| Klein, RG | 1 |
| Pinder, RM | 1 |
| Simon, GE | 1 |
| Heiligenstein, JH | 1 |
| Grothaus, L | 1 |
| Katon, W | 1 |
| Revicki, D | 1 |
| Labbate, LA | 1 |
| Grimes, JB | 1 |
| Hines, A | 1 |
| Allicar, MP | 1 |
| Blachier, C | 1 |
| Nouveau, A | 1 |
| Rouillon, F | 1 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Avci, A | 1 |
| Diler, RS | 1 |
| Tamam, L | 1 |
| Rubey, RN | 1 |
| Johnson, MR | 1 |
| Emmanuel, N | 1 |
| Emslie, GJ | 1 |
| Weinberg, WA | 1 |
| Mayes, TL | 1 |
| Marchesi, C | 1 |
| Ceccherininelli, A | 1 |
| Rossi, A | 1 |
| Maggini, C | 1 |
| Silverstone, PH | 2 |
| Ravindran, A | 1 |
| Farah, A | 1 |
| Bakish, D | 1 |
| Silva, MT | 1 |
| Alves, CR | 1 |
| Santarem, EM | 1 |
| Stevens, T | 1 |
| Katona, C | 1 |
| Manela, M | 1 |
| Watkin, V | 1 |
| Livingston, G | 1 |
| Bech, P | 1 |
| Raabaek Olsen, L | 1 |
| Jarløv, N | 1 |
| Hammer, M | 1 |
| Schütze, T | 1 |
| Breum, L | 1 |
| Nutt, DJ | 1 |
| Nurnberg, HG | 1 |
| Thompson, PM | 1 |
| Hensley, PL | 1 |
| Versiani, M | 1 |
| Ontiveros, A | 1 |
| Mazzotti, G | 1 |
| Ospina, J | 1 |
| Dávila, J | 1 |
| Mata, S | 1 |
| Pacheco, A | 1 |
| Plewes, J | 1 |
| Tamura, R | 1 |
| Palacios, M | 1 |
| Judge, R | 2 |
| Wagner, BE | 1 |
| Michelson, D | 1 |
| Bancroft, J | 1 |
| Targum, S | 1 |
| Kim, Y | 1 |
| Tepner, R | 1 |
| Montgomery, SA | 1 |
| Kantor, S | 1 |
| Graf, M | 1 |
| Anheuer, ZE | 1 |
| Bagdy, G | 1 |
| Garland, EJ | 1 |
| Baerg, EA | 1 |
| Salinas, E | 1 |
| Greene, MA | 1 |
| Dinan, TG | 1 |
| Nash, LT | 1 |
| Cassano, GB | 1 |
| Puca, F | 1 |
| Scapicchio, PL | 1 |
| Trabucchi, M | 1 |
| Novac, A | 1 |
| Pearlman, T | 1 |
| Kafka, MP | 1 |
| Fernandez, F | 1 |
| Levy, JK | 1 |
| Stokes, PE | 1 |
| Bihari, K | 1 |
| Pato, MT | 1 |
| Folgelson, DL | 1 |
| Hoehn-Saric, R | 1 |
| Lipsey, JR | 1 |
| McLeod, DR | 1 |
| Bystritsky, A | 1 |
| Pasnau, RO | 1 |
| Metz, A | 1 |
| Solyom, L | 1 |
| Solyom, C | 1 |
| Ledwidge, B | 1 |
| Herman, JB | 1 |
| Brotman, AW | 1 |
| Falk, WE | 1 |
| Biederman, J | 1 |
| Giesecke, ME | 1 |
| Schneier, FR | 1 |
| Liebowitz, MR | 3 |
| Davies, SO | 2 |
| Hollander, E | 2 |
| Campeas, R | 1 |
| Klein, DF | 2 |
| Sholomskas, AJ | 1 |
| Decaria, C | 1 |
| Gorman, JM | 1 |
| Fyer, AJ | 1 |
| Goetz, D | 1 |
| Campeas, RB | 1 |
| Fyer, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke[NCT02683213] | Phase 3 | 1,500 participants (Actual) | Interventional | 2014-10-20 | Completed | ||
| A Sequential Multiple Assignment Randomized Trial (SMART) Assessing Medication and CBT Sequencing Strategies in the Treatment of Predominantly Ethnic Minority, Underserved Youth With Anxiety Disorders[NCT04760275] | Phase 3 | 404 participants (Anticipated) | Interventional | 2021-02-10 | Recruiting | ||
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| Randomized Controlled Study on the Effect of Pharmacogenomics on Individualized Precise Treatment of Patients With Depression[NCT05669391] | 120 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Using Smartphones to Enhance the Treatment of Childhood Anxiety[NCT02259036] | 40 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| Evaluating a Multi-component Group Intervention for Improving Psychological Well-being of Trainee Civil Servants in Pakistan: a Randomised Controlled Study[NCT03762421] | 240 participants (Actual) | Interventional | 2018-12-01 | Completed | |||
| Building and Sustaining Interventions for Children (BASIC): Task-sharing Mental Health Care in Low-resource Settings[NCT03243396] | 2,880 participants (Anticipated) | Interventional | 2018-02-01 | Enrolling by invitation | |||
| The Effectiveness and Cost-effectiveness of a Collaborative Stepped Care Intervention for the Treatment of Common Mental Disorders in Primary Care Settings in Goa, India[NCT00446407] | 2,796 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Effectiveness of Non-medical Health Worker (NMHW) Led Counseling on Common Mental Disorders in Rural Mid-western Nepal[NCT03544450] | 287 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| Development and Evaluation of an Internet-based Cognitive Behaviour Therapy for Women With Premenstrual Syndrome (PMS)[NCT01961479] | 174 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| [NCT00000381] | Phase 3 | 0 participants | Interventional | 1997-06-30 | Completed | ||
| Increasing Access to Evidence-based Treatments for Depression: The Development and Evaluation of a Digital Training Platform for Interpersonal Psychotherapy.[NCT04619615] | 44 participants (Actual) | Interventional | 2020-07-27 | Active, not recruiting | |||
| Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312] | 402 participants (Anticipated) | Interventional | 2022-07-30 | Active, not recruiting | |||
| Silymarin Treatment of Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Study[NCT02843451] | Phase 2 | 0 participants (Actual) | Interventional | 2016-10-31 | Withdrawn (stopped due to Focus on other studies) | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
22 reviews available for fluoxetine and Anxiety Neuroses
| Article | Year |
|---|---|
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Anxiety; Anxiety Disorders; Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Stroke | 2021 |
Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review.
Topics: Adolescent; Anxiety Disorders; Autism Spectrum Disorder; Citalopram; Comorbidity; Female; Fluoxetine | 2019 |
Six decades of preventing and treating childhood anxiety disorders: a systematic review and meta-analysis to inform policy and practice.
Topics: Adolescent; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Fluoxetine; Humans; Randomized C | 2019 |
[Subjective cognitive complaint. From anxiety to prodromal Alzheimer's disease?].
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognition Diso | 2013 |
Biomarkers for assessing population and individual health and disease related to stress and adaptation.
Topics: Adaptation, Psychological; Allostasis; Animals; Antidepressive Agents, Second-Generation; Anxiety; A | 2015 |
[Use of psychotropic drugs in children].
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Dis | 2008 |
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Act | 1999 |
Pharmacotherapy in depressed children and adolescents.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Child; Combined Modality | 2011 |
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Ma | 2002 |
Pharmacologic management of anxiety disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodiazepines; Child; Flu | 2003 |
[Panic attacks and panic disorder. Checklist for the diagnosis].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
[Neuroadaptive changes in brain during selective serotonin reuptake inhibitors action].
Topics: Adaptation, Physiological; Animals; Anxiety Disorders; Depression; Fluoxetine; Humans; Selective Ser | 2007 |
Current knowledge of medications for the treatment of childhood anxiety disorders.
Topics: Adolescent; Age of Onset; Anti-Anxiety Agents; Anxiety Disorders; Child; Clomipramine; Fluoxetine; H | 1995 |
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Dep | 1994 |
Pharmacological therapy of dysthymia.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzamides; Benzodiazepines; Depressive Disorde | 1994 |
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Comorbidity; Depressive Disorder; Double | 1994 |
Serotonin receptor specificity in anxiety disorders.
Topics: Anxiety Disorders; Buspirone; Fluoxetine; Humans; Receptors, Serotonin; Selective Serotonin Reuptake | 1996 |
The patient with comorbid depression and anxiety: the unmet need.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
The pharmacological treatment of anxiety disorders in children and adolescents.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Child, Presch | 2002 |
Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antidepressive Agents; Anxiety Disorders; Bupropion; Depr | 1991 |
The changing horizon in the treatment of depression: scientific/clinical publication overview.
Topics: Adolescent; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Dep | 1991 |
44 trials available for fluoxetine and Anxiety Neuroses
| Article | Year |
|---|---|
Changes of brain-derived neurotrophic factors in rats with generalized anxiety disorder before and after treatment.
Topics: Animals; Anxiety Disorders; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Fluoxetine; Male; | 2022 |
Change in dysfunctional attitudes and attachment in interpersonal psychotherapy for depressed adolescents.
Topics: Adolescent; Anxiety; Anxiety Disorders; Attitude; Child; Fluoxetine; Humans; Interpersonal Psychothe | 2021 |
A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders.
Topics: Adolescent; Animals; Anxiety Disorders; Cats; Child; Cognitive Behavioral Therapy; Fluoxetine; Human | 2021 |
Fear, avoidance and physiological symptoms during cognitive-behavioral therapy for social anxiety disorder.
Topics: Adult; Anxiety Disorders; Avoidance Learning; Cognitive Behavioral Therapy; Combined Modality Therap | 2013 |
Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents.
Topics: Adolescent; Anxiety Disorders; Child; Clomipramine; Double-Blind Method; Female; Fluoxetine; Humans; | 2013 |
The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design.
Topics: Adolescent; Adult; Animals; Antidepressive Agents; Anxiety Disorders; Attention Deficit Disorder wit | 2014 |
Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; | 2014 |
[The Effectiveness of Cognitive Behavioral Therapy, Medication, or Combined Treatment For Child Hood Anxiety Disorders].
Topics: Anti-Anxiety Agents; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Combined Modality Thera | 2016 |
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depress | 2008 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial.
Topics: Adolescent; Adult; Aged; Allied Health Personnel; Antidepressive Agents; Anxiety Disorders; Cooperat | 2010 |
Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Belgium; Cyclo | 2002 |
Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes.
Topics: Adaptation, Psychological; Administration, Oral; Adult; Anxiety Disorders; Cognitive Behavioral Ther | 2002 |
Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study.
Topics: Adolescent; Anxiety Disorders; Child; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; | 2002 |
Fluoxetine for the treatment of childhood anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Female; Fluoxetine; Humans; Male; Selective Serotonin Reuptake | 2003 |
Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans.
Topics: Adult; Anxiety Disorders; Cardiac Output; Central Nervous System Stimulants; Death, Sudden, Cardiac; | 2003 |
Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cohort Studie | 2004 |
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Double-Blind M | 2006 |
Impact of depressive symptoms on the treatment of generalized social anxiety disorder.
Topics: Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depr | 2005 |
Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial.
Topics: Adolescent; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; Follow-Up Studies; Hu | 2005 |
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Depression; Depressive Disorder; Double-Blin | 2005 |
fMRI predictors of treatment outcome in pediatric anxiety disorders.
Topics: Adolescent; Amygdala; Anti-Anxiety Agents; Anxiety Disorders; Child; Cognitive Behavioral Therapy; E | 2007 |
Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder.
Topics: Adult; Age of Onset; Anxiety Disorders; Comorbidity; Depression; Dysthymic Disorder; Female; Fluoxet | 2006 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsyc | 2007 |
Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognitive Behavioral Therapy; De | 2008 |
Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy.
Topics: Anxiety Disorders; Borderline Personality Disorder; Cognitive Behavioral Therapy; Combined Modality | 2007 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; | 1994 |
Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method; Drug Therapy, Combina | 1993 |
The effect of fluoxetine on anxiety and depression symptoms in cancer patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Doubl | 1996 |
Anxious depression in elderly patients. Response to antidepressant treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Combined Modality Therapy; Depres | 1997 |
Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.
Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; | 1997 |
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine.
Topics: Adult; Aged; Anxiety Disorders; Comorbidity; Depressive Disorder; Drug Administration Schedule; Fema | 1998 |
Fluoxetine in the treatment of anger: an open clinical trial.
Topics: Adult; Ambulatory Care; Anger; Anxiety Disorders; Depressive Disorder; Female; Fluoxetine; Humans; M | 1996 |
Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; | 1998 |
Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; An | 1998 |
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidi | 1999 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluox | 1999 |
Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trial | 1999 |
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Administration Sc | 1999 |
Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; An | 1999 |
Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention.
Topics: Adult; Amantadine; Anxiety Disorders; Buspirone; Depressive Disorder; Dopamine Agents; Female; Fluox | 2000 |
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disord | 2001 |
Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; D | 2001 |
Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
Topics: Affect; Age Factors; Aged; Ambulatory Care; Anxiety Disorders; Cognition; Depressive Disorder; Doubl | 2002 |
Initial reaction and subsequent response to antidepressants in panic patients.
Topics: Anxiety Disorders; Desipramine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluo | 1990 |
101 other studies available for fluoxetine and Anxiety Neuroses
| Article | Year |
|---|---|
Heart rate variability: A biomarker of selective response to mindfulness-based treatment versus fluoxetine in generalized anxiety disorder.
Topics: Anxiety; Anxiety Disorders; Biomarkers; Fluoxetine; Heart Rate; Humans; Mindfulness | 2021 |
Cameron lesions and selective serotonin reuptake inhibitors: An uncommon combination.
Topics: Aged; Anxiety Disorders; Female; Fluoxetine; Gastrointestinal Hemorrhage; Gastroscopy; Hernia, Hiata | 2020 |
The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders.
Topics: Adolescent; Anxiety Disorders; Child; Cytochrome P-450 CYP2D6; Depressive Disorder; Female; Fluoxeti | 2020 |
Perinatal fluoxetine treatment and dams' early life stress history alter affective behavior in rat offspring depending on serotonin transporter genotype and sex.
Topics: Affect; Animals; Animals, Newborn; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Anim | 2020 |
An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Stud | 2020 |
When worry is excessive: Easing the burden of GAD.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Behavior Therapy; Female; Fluoxetine; Humans; Patient | 2020 |
Topics: Adolescent; Anxiety Disorders; Fluoxetine; Humans; Meta-Analysis as Topic; Selective Serotonin Reupt | 2021 |
The combination of fluoxetine and environmental enrichment reduces postpartum stress-related behaviors through the oxytocinergic system and HPA axis in mice.
Topics: Animals; Anxiety; Anxiety Disorders; Brain; Depression, Postpartum; Disease Models, Animal; Female; | 2021 |
β-sitosterol reduces anxiety and synergizes with established anxiolytic drugs in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Fear; Fluoxetine; Mice, Inbred C57BL; Moto | 2021 |
Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Corticosterone; Depres | 2017 |
Perinatal exposure to venlafaxine leads to lower anxiety and depression-like behavior in the adult rat offspring.
Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Animals, Newborn; Anxiety; Anxiety Disorders; Behavio | 2018 |
Fibroblast growth factor 2 is necessary for the antidepressant effects of fluoxetine.
Topics: Animals; Antidepressive Agents; Anxiety Disorders; Behavior, Animal; Depressive Disorder; Disease Mo | 2018 |
Antidepressant Prescription Patterns in Bipolar Disorder: a Nationwide, Register-based Study in Korea.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disor | 2018 |
Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
Topics: Absenteeism; Adolescent; Adolescent Behavior; Anxiety Disorders; Cognitive Behavioral Therapy; Combi | 2019 |
Antidepressant-like activities of live and heat-killed Lactobacillus paracasei PS23 in chronic corticosterone-treated mice and possible mechanisms.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Brain; Corticosterone; | 2019 |
Fluoxetine-related mania in an adolescent girl diagnosed with selective mutism: A case report.
Topics: Adolescent; Anxiety Disorders; Bipolar Disorder; Female; Fluoxetine; Humans; Mutism; Selective Serot | 2020 |
Animal behavior case of the month. Underlying anxiety disorder in an aggressive dog.
Topics: Aggression; Animals; Anxiety Disorders; Behavior, Animal; Dog Diseases; Dogs; Fluoxetine; Male; Sele | 2013 |
Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs.
Topics: Aggression; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorder | 2014 |
Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior.
Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Anxiety Disorders; Butyr | 2014 |
Add neurons, subtract anxiety.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Dentate Gyrus; Fluoxetine; Hip | 2014 |
[Paroxysmal events after anxiety treatment with fluoxetine in a child with autism spectrum disorder].
Topics: Anti-Anxiety Agents; Anxiety Disorders; Child; Child Development Disorders, Pervasive; Comorbidity; | 2014 |
Perinatal vs genetic programming of serotonin states associated with anxiety.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain; Citalopram; Disease Mod | 2015 |
Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antidepressive | 2016 |
The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
Topics: Adolescent; Anxiety Disorders; Child; Cytokines; Depressive Disorder, Major; Enzyme-Linked Immunosor | 2016 |
Fluoxetine normalizes the effects of prenatal maternal stress on depression- and anxiety-like behaviors in mouse dams and male offspring.
Topics: Animals; Animals, Newborn; Anxiety Disorders; Corticosterone; Depressive Disorder; Disease Models, A | 2016 |
Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.
Topics: Acetylcholine; Administration, Oral; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Di | 2016 |
Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala.
Topics: Amygdala; Animals; Anxiety; Anxiety Disorders; Corticotropin-Releasing Hormone; Dorsal Raphe Nucleus | 2016 |
Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: impact of the serotonin pathway.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Mental | 2016 |
Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, | 2017 |
Innovative child and adolescent treatment research for anxiety and depressive disorders.
Topics: Adolescent; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depre | 2009 |
Trismus induced by fluoxetine.
Topics: Anxiety Disorders; Depressive Disorder, Major; Fluoxetine; Humans; Male; Middle Aged; Selective Sero | 2009 |
Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Animals, Newborn; Anxiety Disorders; CREB-Binding P | 2010 |
A preliminary investigation of neural correlates of treatment in adolescents with generalized anxiety disorder.
Topics: Adolescent; Anxiety Disorders; Cognitive Behavioral Therapy; Emotions; Facial Expression; Female; Fl | 2010 |
Anxiety as a predictor of treatment outcome in children and adolescents with depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, | 2010 |
The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Anxiety Disorders; Attention; Comorbidity; | 2010 |
Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Majo | 2010 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Cell Proliferati | 2012 |
Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressi | 2012 |
Fear erasure in mice requires synergy between antidepressant drugs and extinction training.
Topics: Amygdala; Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Behavior Therapy; Br | 2011 |
Prenatal lipopolysaccharide exposure increases anxiety-like behaviors and enhances stress-induced corticosterone responses in adult rats.
Topics: Animals; Anxiety; Anxiety Disorders; Brain; Corticosterone; Dopamine; Female; Fluoxetine; Hippocampu | 2012 |
Genetic strain differences in learned fear inhibition associated with variation in neuroendocrine, autonomic, and amygdala dendritic phenotypes.
Topics: Amygdala; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders | 2012 |
Rapid response to fluoxetine in women with premenstrual dysphoric disorder.
Topics: Adult; Analysis of Variance; Anxiety Disorders; Depressive Disorder; Drug Administration Schedule; F | 2012 |
Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder | 2002 |
What is best for the patient?
Topics: Aged; Anxiety Disorders; Cardiovascular Diseases; Dementia; Evidence-Based Medicine; Fluoxetine; Ger | 2003 |
Fluoxetine decreases stereotypic behavior in primates.
Topics: Animals; Anxiety Disorders; Chlorocebus aethiops; Disease Models, Animal; Female; Fluoxetine; Male; | 2003 |
Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Major; Doub | 2003 |
The pineal gland and anxiogenic-like action of fluoxetine in mice.
Topics: Animals; Anxiety Disorders; Arylamine N-Acetyltransferase; Denervation; Fluoxetine; Male; Melatonin; | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal | 2005 |
Pharmacological evaluation of the stress-induced social avoidance model of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Buspirone; Chlordiazepoxide; Diazepam; Disea | 2006 |
Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?
Topics: Adolescent; Age Factors; Anxiety Disorders; Child; Clinical Trials as Topic; Depressive Disorder, Ma | 2006 |
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
Topics: Adolescent; Adult; Aged; Anger; Anxiety Disorders; Depressive Disorder, Major; Diagnostic and Statis | 2007 |
Learned helplessness is independent of levels of brain-derived neurotrophic factor in the hippocampus.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Avoidance Learning; Brain-Deri | 2007 |
Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Dis | 2008 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord | 2007 |
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Aggression; Animals; Anti-Anxiety Age | 2008 |
Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Arousal | 2008 |
Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.
Topics: Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Child; Child, Preschool; Depression; Dr | 2008 |
Case study: fluoxetine in the multimodal treatment of a preschool child with selective mutism.
Topics: Anxiety Disorders; Child Behavior Disorders; Child, Preschool; Combined Modality Therapy; Female; Fl | 1995 |
Fluoxetine for childhood anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Psychia | 1994 |
Prescription-event monitoring of 10,401 patients treated with fluvoxamine.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Depressive Disorder; Drug Monitoring; Drug Prescriptions | 1994 |
Fluoxetine in anxiety disorders.
Topics: Anxiety Disorders; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; Dose-Respon | 1994 |
Pharmacologic management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depression; Dopamine; Fluox | 1994 |
Sexual dysfunction during antidepressant treatment.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depressive Disorder; | 1993 |
Euphoria with buspirone after fluoxetine treatment.
Topics: Aged; Alzheimer Disease; Anxiety Disorders; Buspirone; Euphoria; Female; Fluoxetine; Humans; Male | 1993 |
Body dysmorphic disorder: 30 cases of imagined ugliness.
Topics: Adolescent; Adult; Age Factors; Aged; Agoraphobia; Anxiety Disorders; Body Image; Clomipramine; Delu | 1993 |
Fluoxetine withdrawal symptoms.
Topics: Adult; Anxiety Disorders; Dizziness; Fluoxetine; Humans; Male; Middle Aged; Substance Withdrawal Syn | 1996 |
Hepatitis secondary to fluoxetine treatment.
Topics: Adult; Anxiety Disorders; Chemical and Drug Induced Liver Injury; Clonazepam; Drug Therapy, Combinat | 1996 |
Treatment of palilalia with trazodone.
Topics: Adult; Anxiety Disorders; Chemical and Drug Induced Liver Injury; Clonazepam; Drug Therapy, Combinat | 1996 |
The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders.
Topics: Anxiety Disorders; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Follow-U | 1996 |
Serotonin, psilocybin, and body dysmorphic disorder: a case report.
Topics: Adult; Anxiety Disorders; Body Image; Fluoxetine; Humans; Male; Perceptual Distortion; Psilocybin; S | 1996 |
Two-year outcome of elderly patients with anxious depression.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, Dru | 1997 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |
The pharmacologic rationale for the clinical use of antidepressants.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; | 1997 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Dis | 1997 |
Which patients receive antidepressants? A 'real world' telephone study.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; A | 1998 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |
Fluoxetine treatment in a 2.5-year-old girl.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Child, Preschool; Female; Fluoxetine; Humans | 1998 |
Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze.
Topics: Analysis of Variance; Animals; Anxiety Disorders; Fluoxetine; Food Deprivation; Male; Maze Learning; | 1999 |
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.
Topics: Amines; Antidepressive Agents; Anxiety Disorders; Dehydroepiandrosterone; Depressive Disorder, Major | 1999 |
Once-daily venlafaxine XR compared with fluoxetine in outpatients with depression and anxiety.
Topics: Anxiety Disorders; Comorbidity; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Flu | 1999 |
Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clomipramine; Depressive Disorder, Major; Fluox | 2000 |
Rapid desensitization of 5-HT(1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety Disorders; Body Temperature; Depressive Dis | 2001 |
Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Motivat | 2001 |
The effects of the introduction of medication on the psychoanalytic process: a case study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Combined Modality Therapy; Defen | 2001 |
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD.
Topics: Anxiety Disorders; Bipolar Disorder; Bupropion; Drug Therapy, Combination; Fluoxetine; Humans; Infan | 1992 |
Fluoxetine and suicidality.
Topics: Akathisia, Drug-Induced; Anxiety Disorders; Basal Ganglia Diseases; Depressive Disorder; Dose-Respon | 1992 |
Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications.
Topics: Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Cocaine; Depressive Disorder; Feeding and | 1991 |
Successful treatment of paraphilic coercive disorder (a rapist) with fluoxetine hydrochloride.
Topics: Anxiety Disorders; Child of Impaired Parents; Combined Modality Therapy; Depressive Disorder; Fantas | 1991 |
Neurologic soft signs in obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Central Nervous System Diseases; Clomipramine; Clonidine; Depressive Disor | 1991 |
Weight gain during fluoxetine treatment.
Topics: Adolescent; Adult; Anxiety Disorders; Body Weight; Female; Fluoxetine; Humans; Male; Middle Aged | 1991 |
Apathy and indifference in patients on fluvoxamine and fluoxetine.
Topics: Adult; Agoraphobia; Antidepressive Agents; Anxiety Disorders; Arousal; Depressive Disorder; Dose-Res | 1990 |
Interaction between fluoxetine and buspirone.
Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Buspirone; Depressive Disorder; Drug Therapy, Com | 1990 |
The fluoxetine treatment of low-weight, chronic bulimia nervosa.
Topics: Adult; Anxiety Disorders; Body Weight; Bulimia; Depressive Disorder; Feeding Behavior; Female; Fluox | 1990 |
Fluoxetine-induced sexual dysfunction.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Depressive Disorder; Female; Fluoxetine; Humans; Male; Mi | 1990 |
Overcoming hypersensitivity to fluoxetine in a patient with panic disorder.
Topics: Adult; Akathisia, Drug-Induced; Anxiety Disorders; Drug Administration Schedule; Fear; Fluoxetine; H | 1990 |
Fluoxetine in panic disorder.
Topics: Adult; Agoraphobia; Anxiety Disorders; Benzodiazepines; Fear; Female; Fluoxetine; Humans; Male; Pani | 1990 |
Mania in a panic disorder patient treated with fluoxetine.
Topics: Adult; Alprazolam; Anxiety Disorders; Bipolar Disorder; Fear; Fluoxetine; Humans; Male; Panic | 1990 |
Pharmacological dissection of panic and depersonalization.
Topics: Adolescent; Alprazolam; Anxiety Disorders; Depersonalization; Fear; Female; Fluoxetine; Humans; Imip | 1989 |
An open trial of fluoxetine in the treatment of panic attacks.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Fear; Female; Fluoxetine; Humans; Male; Middle Aged | 1987 |